Vascular Wall Reactions to Coronary Stents—Clinical Implications for Stent Failure

Gori, Tommaso

doi:10.3390/life11010063

Cited by 17 publications

(12 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous study demonstrated that LSM may cause stent thrombosis. Compared with the control group, the incidence of SM in patients with very advanced thrombosis (77 vs. 12%, respectively; P<0.001) and the area of SM (77 vs. 12%, respectively; P<0.001) were significantly increased ( 68 ). A total of 20 cases of late and very late stent thrombosis were examined through OCT, indicating that 11 cases (55%) had SM, of which 5 cases had LSM caused by abnormal positive remodeling of the vessel wall ( 68 ).…”

Section: Application Of Oct In the Post-stent Implantation Follow-upmentioning

confidence: 84%

“…Compared with the control group, the incidence of SM in patients with very advanced thrombosis (77 vs. 12%, respectively; P<0.001) and the area of SM (77 vs. 12%, respectively; P<0.001) were significantly increased ( 68 ). A total of 20 cases of late and very late stent thrombosis were examined through OCT, indicating that 11 cases (55%) had SM, of which 5 cases had LSM caused by abnormal positive remodeling of the vessel wall ( 68 ). However, the incidence of LSM is notably higher than the incidence of late stent thrombosis, indicating that, although LSM may not be the sole cause of stent thrombosis, it may be one of the critical factors contributing to the formation of stent thrombosis.…”

Section: Application Of Oct In the Post-stent Implantation Follow-upmentioning

confidence: 84%

See 1 more Smart Citation

Advantages and prospects of optical coherence tomography in interventional therapy of coronary heart disease (Review)

Wang

Yuan

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

Coronary heart disease is the leading cause of mortality among all diseases globally. Percutaneous coronary intervention (PCI) is a key method for the treatment of coronary heart disease. Optical coherence tomography (OCT) is an optical diagnostic technology with a resolution of up to 10 µm, which is able to accurately assess the composition of the coronary arterial wall and determine the characteristics of atherosclerotic lesions. It is also highly consistent with pathological examinations, optimizing the effect of stent implantation and evaluation of the long-term effectiveness and safety of the stent, which has irreplaceable value in the field of precision and optimization of coronary intervention. The innovative OCT technology may help provide more comprehensive clinical research evidence. The application of OCT in clinical and basic research of coronary atherosclerosis, selection of treatment strategies for acute coronary syndromes, optimization of interventional treatment efficacy, evaluation of novel stents, intimal stent coverage and selection of dual antiplatelet drugs has become more widely used, affecting the current coronary interventional treatment strategies to a certain extent. The aim of the present review was to discuss the role of OCT in evaluating preoperative plaque characteristics, guiding PCI and evaluating the effects of postoperative stents or drug treatments.

show abstract

Section: Application Of Oct In the Post-stent Implantation Follow-upmentioning

confidence: 84%

Section: Application Of Oct In the Post-stent Implantation Follow-upmentioning

confidence: 84%

Advantages and prospects of optical coherence tomography in interventional therapy of coronary heart disease (Review)

Wang

Yuan

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…In this context, thrombin also has potent mitogen effects, and the immunosuppressive effect of the drug eluted might slow tissue repair reaction and fibrin removal. The prolonged activation of the thrombotic cascade concurs with the activation of inflammatory cells (monocytes, T cells, neutrophils), secretion of chemoattractant molecules (MCP-1 or monocyte chemoattractant protein-1, Interleukin (IL)-8) by endothelial and SMCs and the production of growth factors (PDGF, platelet-derived growth factor, bFGF or fibroblast growth factor, TGF or transforming growth factor-beta, IGF, insulin-like growth factor, and VEGF, vascular endothelial growth factor [23]). Platelet-derived extracellular vesicles stimulate SMCs to produce interleukin 6 and express α IIb β 3 and P-selectin, which favor their interaction with monocytes [24].…”

Section: Cells Involved In the Pathophysiology Of In-stent Restenosismentioning

confidence: 94%

Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist)

Gori¹

2022

Cells

Self Cite

View full text Add to dashboard Cite

Coronary stents are among the most common therapies worldwide. Despite significant improvements in the biocompatibility of these devices throughout the last decades, they are prone, in as many as 10–20% of cases, to short- or long-term failure. In-stent restenosis is a multifactorial process with a complex and incompletely understood pathophysiology in which inflammatory reactions are of central importance. This review provides a short overview for the clinician on the cellular types responsible for restenosis with a focus on the role of endothelial progenitor cells. The mechanisms of restenosis are described, along with the cell-based attempts made to prevent it. While the focus of this review is principally clinical, experimental evidence provides some insight into the potential implications for prevention and therapy of coronary stent restenosis.

show abstract

“…The pro-thrombotic risk is possible to diminish with the use of corresponding drugs, such as Aspirin + P2Y12 inhibitors. This makes drug-eluting stents a better choice in comparison with bare-metal stents [52].…”

Section: Mtor Modulation In Atherosclerosismentioning

confidence: 99%

Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis

Poznyak

Sukhorukov

Zhuravlev

et al. 2022

IJMS

View full text Add to dashboard Cite

For more than a decade, atherosclerosis has been one of the leading causes of death in developed countries. The issue of treatment and prevention of the disease is especially acute. Despite the huge amount of basic and clinical research, a significant number of gaps remain in our understanding of the pathogenesis of atherosclerosis, and only their closure will bring us closer to understanding the causes of the disease at the cellular and molecular levels and, accordingly, to the development of an effective treatment. One of the seemingly well-studied elements of atherogenesis is the mTOR signaling pathway. However, more and more new details are still being clarified. Therapeutic strategies associated with rapamycin have worked well in a number of different diseases, and there is every reason to believe that targeting components of the mTOR pathway may pay off in atherosclerosis as well.

show abstract

Vascular Wall Reactions to Coronary Stents—Clinical Implications for Stent Failure

Cited by 17 publications

References 76 publications

Advantages and prospects of optical coherence tomography in interventional therapy of coronary heart disease (Review)

Advantages and prospects of optical coherence tomography in interventional therapy of coronary heart disease (Review)

Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist)

Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis

Contact Info

Product

Resources

About